A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)

American Heart Journal

Volumn 134, Issue 1, 1997, Pages 44-54

  Califf, R M ^a   Adams, K F ^a   McKenna, W J ^a   Gheorghiade, M ^a   Uretsky, B F ^a   McNulty, S E ^a   Darius, H ^a   Schulman, K ^a   Zannad, F ^a   Handberg Thurmond, E ^a   Harrell F E , Jr ^a   Wheeler, W ^a   Soler Soler, J ^a   Swedberg, K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; NITRATE; PROSTACYCLIN;

ADULT; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; ENZYME INHIBITION; HUMAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VASCULAR RESISTANCE;

EID: 0030853952     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(97)70105-4     Document Type: Article

References (39)

1. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
2. JN Cohn DG Archibald S Ziesche JA Franciosa WE Harston FE Tristani Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N Engl J Med 314 1986 1547 1552
3. M Packer M Gheorghiade JB Young PJ Constantini KF Adams RJ Cody Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study N Engl J Med 329 1993 1 7
4. WA Knaus FE Harrell Jr J Lynn L Goldman RS Phillips AF Connors The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments Ann Intern Med 122 1995 191 203
5. H Patterson KF Adams Jr M Gheorghiade RL Bourge CA Sueta SW Clarke Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure Am J Cardiol 75 1995 26A 33A
6. K Kubo T Kobayashi K Yoshimura M Fukushima K Handa S Kusama Hemodynamic responses to prostacyclin (PGI2) in the conscious sheep Jpn Circ J 46 1982 1292 1304
7. RJ Gryglewski S Bunting S Moncada RJ Flower JR Vane Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides Prostaglandins 12 1976 685 713
8. BF Jugdutt GM Hutchins BH Bulkley LC Becker Infarct size reduction by prostacyclin after coronary occlusion in conscious dogs Clin Res 27 1979 177A
9. ML Ogletree AM Lefeer JB Smith KC Nicolaou Studies on the protective effect of prostacyclin in acute myocardial ischemia Eur J Pharmacol 56 1979 95 103
10. LGT Ribeiro TA Brandon DG Hopkins LA Reduto AA Taylor RR Miller Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality Am J Cardiol 47 1981 835 840
11. AL Willis DL Smith C Vigo AF Kluge Effects of prostacyclin and orally stable mimetic agent RS-93427-007 on basic mechanisms of atherogenesis Lancet ii 1987 682 683
12. LJ Rubin J Mendoza M Hood M McGoon R Barst WB Williams Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 1990 485 491
13. RJ Barst LJ Rubin MD McGoon EJ Caldwell WA Long PS Levy Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin Ann Intern Med 121 1994 409 415
14. RJ Barst LJ Rubin WA Long MD McGoon S Rich DB Badesch A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 301
15. DP Hajjar Prostaglandins and cyclic nucleotides: modulators of arterial cholesterol metabolism Biochem Pharmacol 34 1985 295 300
16. CA Sueta M Gheorghiade KF Adams Jr RL Bourge S Murali BF Uretsky for the Epoprostenol Multicenter Research Group Safety and efficacy of epoprostenol in patients with severe congestive heart failure Am J Cardiol 75 1995 34A 43A
17. DC Lee RA Johnson JB Bingham M Leahy RE Dinsmore AH Goroll Heart failure in outpatients: a randomized trial of digoxin versus placebo N Engl J Med 306 1982 699 705
18. R Rosser H Sintonen The EuroQol quality of life project SR Walker RM Rosser Quality of life assessment: key issues in the 1990s 1993 Kluwer Academic Publishers Dordrecht 197 199
19. GH Guyatt S Nogradi S Halcrow J Singer MJ Sullivan EL Fallen Development and testing of a new measure of health status for clinical trials in heart failure J Gen Intern Med 4 1989 101 107
20. SM Hunt SP McKenna J McEwen J Williams E. Papp The Nottingham Health Profile: subjective health status and medical consultations Soc Sci Med 15 1981 221 229
21. J. Whitehead I Stratton Group sequential clinical trials with triangular continuation regions Biometrics 39 1983 227 236
22. RJ Barst LS Rubin WA Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 302
23. M Packer KA Narahara U Elkayam JM Sullivan DL Pearle BM Massie Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal investigators of the REFLECT Study J Am Coll Cardiol 22 1993 65 72
24. KB Swedberg M Packer JL Rouleau Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study J Am Coll Cardiol Special Issue xiii 1994
25. M Packer WH Lee N Medina M Yushak JL Bernstein PD Kessler Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction J Am Coll Cardiol 10 1987 1303 1311
26. JE Muller J Morrison PH Stone RE Rude B Rosner R Roberts Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison Circulation 69 1984 740 747
27. CD Furberg BM Psaty JV. Meyer Nifedipine. Dose-related increase in mortality in patients with coronary heart disease Circulation 92 1995 1326 1331
28. PH Held S Yusuf Effects of beta-blockers and calcium channel blockers in acute myocardial infarction Eur Heart J 14 Suppl F 1993 18 25
29. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 319 1988 385 392
30. M Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 20 1992 248 254
31. C Patrono F Pugliese G Ciabattoni P Patrignani A Masseri S Chierchia Evidence for a direct stimulatory effect of prostacyclin on renin release in man J Clin Invest 69 1982 231 239
32. SM Lanier KU Malik Inhibition by prostaglandins of adrenergic transmission in the left ventricular myocardium of anesthetized dogs J Cardiovasc Pharmacol 7 1985 653 659
33. H Steinberg OS Medvedev FC Luft T Unfger Effect of a prostacyclin derivative (iloprost) on regional blood flow, sympathetic nerve activity and baroreceptor reflex in the conscious rat J Cardiovasc Pharmacol 11 1988 84 89
34. D Elsner EP Kromer GA Riegger Hemodynamic, hormonal and renal effects of the prostacyclin analogue iloprost in conscious dogs with and without heart failure J Cardiovasc Pharmacol 16 1990 601 608
35. F Arzilli R Giovannetti M. Lenzi A Salvetti Acute hemodynamic (systemic and renal) and humoral effects of three increasing doses of iloprost in essential hypertensives Am J Hypertension 2 1989 856 860
36. P Ylitalo S Kaukinen AK Nurmi E Seppala T Pessi H Vapaatalo Effects of a prostacyclin analog iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoids and catecholamines in man Prostaglandins 29 1985 1063 1071
37. Y Yui H Nakajima C Kawai T Murakami Prostacyclin therapy in patients with congestive heart failure Am J Cardiol 50 1981 320 324
38. H Nishikawa Intravenous vasodilator therapy in patients with refractory congestive heart failure (CHF)—prostaglandin and dibutyryl—cyclic AMP Mie Med J 36 1986 57 83
39. RO Bonow N Galié M Gheorghiade B Magnani Prostacyclin: basic principles and clinical application in congestive heart failure and primary pulmonary hypertension Am J Cardiol 75 Suppl 1995 1A 73A